![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Axsome Therapeutics to Acquire Jazz Pharmaceuticals’ Sleep-Combating Drug Sunosi
Axsome Therapeutics to Acquire Jazz Pharmaceuticals’ Sleep-Combating Drug Sunosi
Jazz Pharmaceuticals agreed to divest its Sunosi (solriamfetol) drug to Axsome Therapeutics that includes an upfront payment of $53 million.
Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor that has FDA and EU approval for treatment of excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea.
Jazz earned $57.9 million from Sunosi sales in 2021, an increase of 104 percent from the previous year.
Upcoming Events
-
18Jul
-
21Oct